December 22, 2011

HELIX BIOPHARMA CORP. FILES CLINICAL TRIAL APPLICATIONS FOR ITS PLANNED EUROPEAN PHASE III EFFICACY TRIAL OF TOPICAL INTERFERON ALPHA-2B IN PATIENTS WITH LOW-GRADE CERVICAL LESIONS (PDF)

AURORA, Ontario, December 22, 2011 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that it has filed a clinical trial application (“CTA”) in both Germany and the United Kingdom, with the Bundesinstitut für Arzneimittel und Medizinprodukte (“BfArM”) and the Medicines and Healthcare Regulatory Authority (“MHRA”) respectively, seeking approval to perform its planned European Phase III efficacy trial of Topical Interferon Alpha-2b in patients with low-grade cervical lesions in one or both jurisdictions.